Evolus, Inc. insider trading
Every open-market purchase and sale by Evolus, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Evolus, Inc.’s insiders pay?
From June 4, 2018 to September 4, 2026, 19 insiders reported 32 open-market purchases and 40 sales not made under a pre-set plan in Evolus, Inc. Twelve months after each purchase was reported, the shares were −31.6% against the S&P 500 on average (median −30.1%), over 32 purchases with a full year of prices; 13% beat the index. After sales, the shares moved −24.6% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 5, 2018 into $1,520 by November 2, 2026, −20.1% a year. It held shares 70% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,866 (+9.2% a year), and held throughout $31,275 (+14.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Medytox Inc. | Other | 8 | +2.2% (8) | 38% | 8 | +1.8% (8) | October 18, 2023 |
| Malik Vikram | Director | 4 | −39.5% (4) | 25% | 5 | −15.7% (5) | June 5, 2024 |
| Moatazedi David | See Remarks | 0 | — | — | 9 | −23.9% (8) | September 4, 2026 |
| Romine Kristine | Director | 7 | −52.6% (7) | 0% | 0 | — | May 31, 2019 |
| Aeon Biopharma, Inc. | 10% owner | 0 | — | — | 5 | −48.6% (5) | June 4, 2019 |
| Gill David N | Director | 2 | −51.4% (2) | 0% | 2 | −34.6% (2) | May 15, 2024 |
| Beaver Sandra | Chief Financial Officer | 0 | — | — | 3 | −43.8% (3) | September 6, 2024 |
| Blank Simone | Director | 3 | −45.0% (3) | 0% | 0 | — | September 8, 2022 |
| Alphaeon 1 LLC | 10% owner | 0 | — | — | 2 | +29.0% (2) | February 22, 2023 |
| Avelar Rui | See Remarks | 0 | — | — | 2 | −29.7% (2) | May 14, 2024 |
| Hau Bosun | Director | 2 | −63.5% (2) | 0% | 0 | — | June 8, 2018 |
| Hayman Robert | Director | 2 | −24.8% (2) | 0% | 0 | — | September 13, 2022 |
| Silvernail Lauren P | See Remarks | 0 | — | — | 2 | −53.2% (2) | May 18, 2022 |
| Farrell Peter C | Director | 1 | −20.5% (1) | 0% | 0 | — | September 6, 2022 |
| Jafar Michael M. | Chief Marketing Officer | 1 | −5.9% (1) | 0% | 0 | — | September 18, 2018 |
| Parschauer Karah Herdman | Director | 0 | — | — | 1 | −82.5% (1) | March 14, 2025 |
| Stewart Brady | Director | 1 | −3.4% (1) | 0% | 0 | — | August 18, 2025 |
| White Albert G III | Director | 1 | −59.0% (1) | 0% | 0 | — | June 10, 2025 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer | 0 | — | — | 1 | −70.5% (1) | September 4, 2024 |
When several insiders traded Evolus, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Evolus, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 5 buying crowds with six months of prices, it averaged −25.9% against the index. After 3 selling crowds, +1.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 29, 2025 | 2 buying | −12.4% | −51.9% | −0.4% |
| March 28, 2024 | 3 selling | −26.9% | +4.0% | −23.0% |
| September 30, 2022 | 3 buying | −14.3% | −10.9% | −11.6% |
| May 31, 2022 | 3 selling | −17.4% | −41.4% | −36.7% |
| September 30, 2021 | 3 selling | −26.0% | +41.3% | +21.2% |
| May 31, 2019 | 2 buying | +9.0% | −13.3% | −75.5% |
| December 31, 2018 | 4 buying | +75.0% | −2.8% | −29.0% |
| June 29, 2018 | 3 buying | −41.1% | −50.6% | −61.7% |